2 active not recruiting, 2 not yet recruiting, 1 completed, 1 recruiting. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Active not recruiting 2, Completed 1, Not yet recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Not yet recruiting 2 |
Follow Cellenkos, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CK0801 for Treatment of Aplastic Anemia CK0801 - Aplastic Anemia | Phase 2 | Not yet recruiting | Cellenkos, Inc. | 12 | 2026-12-03 | 2026-10-20 |
| CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD) CK0802 (Allogeneic, Cryopreserved, Cord blood-derived T-regulatory cells, cells that are not HLA matched) - Steroid Refractory Graft Versus Host Disease | Phase 1 / Phase 2 | Not yet recruiting | Cellenkos, Inc. | 12 | 2026-11-01 | 2026-10-21 |
| Regulatory T Cells for Amyotrophic Lateral Sclerosis CK0803, Excipient - Amyotrophic Lateral Sclerosis | Phase 1 | Active not recruiting | Cellenkos, Inc. | 66 | 2023-04-03 | 2026-10-21 |
| Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs CK0804 - Myelofibrosis | Phase 1 | Recruiting | Cellenkos, Inc. | 24 | 2022-12-27 | 2026-10-21 |
| A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS) CK0801 - Guillain-Barré Syndrome | Phase 1 | Withdrawn | Cellenkos, Inc. | 2022-11-01 | 2023-01-04 | |
| REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia CK0802, Placebo - COVID19, ARDS | Phase 1 | Completed | Cellenkos, Inc. | 45 | 2020-09-29 | 2022-03-10 |
| A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF) CK0801 - Bone Marrow Disease | Phase 1 | Active not recruiting | Cellenkos, Inc. | 18 | 2019-05-30 | 2026-10-21 |
Bone Marrow Diseases (2) · Amyotrophic Lateral Sclerosis (1) · Anemia, Aplastic (1) · Bone Marrow Failure Disorders (1) · Bone Marrow Neoplasms (1) · COVID-19 (1) · Graft vs Host Disease (1) · Guillain-Barre Syndrome (1) · Hematologic Diseases (1) · Myeloproliferative Disorders (1) · Primary Myelofibrosis (1) · Thrombocytosis (1)
Cryopreservation (1) · Excipients (1)
United States (4)
Neil Shneider, MD, PhD (1) · Tapan M Kadia, MD (1) · Tara Sadeghi (1)